 | Mark B AbelsonOphthalmology, Harvard Medical School, Boston, MA, USA | Ophthalmology, Massachusetts Eye and Ear, Boston, MA, USA | Ora, Inc, 300 Brickstone Square, 01810, Andover, MA, USA | ... |
KOL Resume for Mark B Abelson (allergic, rhinitis, disease, vasomotor allergic rhinitis, vasomotor)
| Year | |
|---|---|
| 2020 | Ophthalmology, Harvard Medical School, Boston, MA, USA |
| 2019 | Ora, Inc., Andover, MA, USA |
| 2018 | Department of Ophthalmology, Harvard Medical School, Boston, MA, USA. Ora, Inc., Andover, MA, USA, |
| 2017 | Ora, Inc., 300 Brickstone Square, 01810, Andover, MA, USA Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts. |
| 2016 | Department of Ophthalmology, Harvard University, Andover, Mass |
| 2015 | Ora, Inc., 300 Brickstone Square, Andover MA 01810, USA; Harvard Medical School, Department of Ophthalmology, Boston, MA, USA Harvard Medical School, Boston, Massachusetts, United States |
| 2014 | Ora, Andover, MA, USA |
| 2013 | Ora, Inc, Andover, MA, USA |
| 2012 | Harvard Medical School, Schepens Eye Research Institute, Boston, MA |
| 2011 | Schepens Eye Research Institute, Boston, Massachusetts. ORA, Andover, MA |
| 2010 | Harvard University, Cambridge, MA Schepens Eye Research Institute, Boston, Massachusetts |
| 2009 | Boston, MA Ora, Inc., Andover, Massachusetts |
| 2008 | ORA Clinical Research and Development, North Andover, Massachusetts Chair Emeritus, F. A. Davis Professor and Lorenz F. Zimmerman Professor, Department of Ophthalmology and Visual Sciences, Retina Research Foundation Emmett A. Humble Distinguished Director, of the Alice R. McPherson, MD, Eye Research Institute, University of Wisconsin Medical School, Madison, Wisconsin, USA From the Ophthalmic Research Associates, North Andover, MA. Administrative Director, Alice R. McPherson, MD Eye Research Institute, University of Wisconsin Medical School, Madison, Wisconsin, US |
| 2007 | Ophthalmic Research Associates, North Andover, MA, USA; |
| 2006 | Ophthalmic Research Associates, 863 Turnpike Street, North Andover, MA, 01845 Schepens Eye Research Institute, Harvard Medical School, 20 Staniford Street, Boston, MA, 12114 |
| 2005 | Harvard Medical School and Schepens Eye Research Institute, Boston, MA, and Ophthalmic Research Associates, Inc., North Andover, MA Ophthalmic Research Associates, Inc., North Andover, Massachusetts |
| 2004 | Ophthalmic Research Associates, North Andover, MA, USA; Schepens Eye Research Institute, Boston, MA, USA; Department of Ophthalmology, Harvard Medical School, Boston, MA, USA From the *Department of Ophthalmology, The Georgetown University-Washington Hospital Center, Washington, DC; and †The Eye Research Institute, Harvard Medical School, Boston, MA. Schepens Eye Research Institute, Harvard Medical School, Boston, MA |
| 2003 | Ophthalmic Research Associates, Inc., USA Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute, Boston, Massachusetts |
| 2002 | Ophthalmic Research Associates Dry Eye Department North Andover, Massachusetts, USA Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts |
| 2000 | Department of Ophthalmology, Harvard Medical School, Boston, MA 5 Harvard Medical School and Schepens Eye Research Institute, Boston, MA |
| 1999 | SERI, Boston, Harvard Medial School, Boston Senior Clinical Scientist, Schepens Eye Research Institiute, Associate Professor, Harvard Medical School |
Prominent publications by Mark B Abelson
BACKGROUND: It is presumed that exposure to allergens in the environment occurs through both the eyes and the nose. Allergic rhinoconjunctivitis is typically treated with a nasal spray or systemic antihistamine, neither of which may provide adequate relief of the ocular component of the disease.
OBJECTIVE: This study was designed to gain a better understanding of the physiologic interaction between the conjunctival and nasal mucosa and thus help establish a profile for the most effective ...
| Known for Nasal Spray | Allergen Challenge | Ophthalmic Solution | Mometasone Furoate | Visit Subjects |
BACKGROUND: One approach to treating allergic rhinoconjunctivitis is the concomitant use of an intranasal spray such as fluticasone propionate to alleviate nasal symptoms and a topical or systemic agent to relieve ocular symptoms. It has not yet been determined whether a topical or systemic agent is more effective for the latter purpose.
OBJECTIVE: This study compared the efficacy of combined use of fluticasone and olopatadine with combined use of fluticasone and fexofenadine in the ...
| Known for Allergic Rhinoconjunctivitis | Conjunctival Allergen Challenge | Intranasal Administration | Nasal Symptoms | Visit Subjects |
OBJECTIVE: This study was conducted to compare the efficacy and safety of olopatadine ophthalmic solution (0.1%) with ketorolac ophthalmic solution (0.5%) in a clinical model of acute allergic conjunctivitis. Olopatadine is a dual acting H1 histamine receptor antagonist and a mast cell stabilizer, shown to be effective in treating allergic conjunctivitis. Ketorolac is a non-steroidal anti-inflammatory drug approved in the United States for the relief of ocular itching associated with ...
| Known for Olopatadine Ophthalmic Solution | Ocular Itching | Comparative Evaluation | Eye Placebo | Ketorolac Ophthalmic |
BACKGROUND: Bepotastine besilate is a highly selective histamine H(1)-receptor antagonist with antihistaminic, mast cell stabilizing, and anti-inflammatory activity. Based on a history of clinical effectiveness and tolerability of oral bepotastine besilate in the treatment of allergic symptoms, bepotastine besilate is being tested as a potential ophthalmic medication for allergic conjunctivitis.
OBJECTIVE: The aim of this study was to assess the effects of bepotastine besilate ophthalmic ...
| Known for Bepotastine Besilate | Allergic Conjunctivitis | Ophthalmic Solution | 10 15 | Phase Iii |
Vigabatrin (VGB) is a structural analogue of gamma-aminobutyric acid (GABA) that irreversibly inhibits GABA-transaminase (GABA-T), increasing brain levels of GABA. VGB is under assessment for treatment of infantile spasms (IS) and refractory complex partial seizures (CPS). Response can be rapid with spasm cessation following approximately 2 weeks of therapy. Patients with symptomatic tuberous sclerosis (TS) and other patients have achieved spasm cessation. Comparison with ACTH has been ...
| Known for Vgb Patients | 12 Weeks | Adults Cps | Treatment Infantile Spasms | Visual Field |
OBJECTIVE: The purpose of this study was to assess the effects of olopatadine on the release of mast cell-derived mediators after conjunctival allergen challenge(CAC) in humans.
METHODS: This was a double-masked, randomized, placebo-controlled clinical trial. Subjects with a clinical history of seasonal allergic conjunctivitis (but no current symptoms or treatment at baseline) were studied. At visit 1, subjects underwent bilateral CAC with increasing doses of allergen every 15 minutes ...
| Known for Mast Cell | Olopatadine Placebo | Visit Subjects | Conjunctival Allergen | Itching Redness |
Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis
[ PUBLICATION ]
Olopatadine hydrochloride ophthalmic solution 0.2% (Pataday, Alcon) is a new formulation of olopatadine hydrochloride ophthalmic solution, the first topical ocular antiallergic agent indicated for once-daily dosing. The aim of this study was to evaluate the safety, efficacy, onset, and duration of action of olopatadine 0.2% in the treatment of allergic conjunctivitis. Using the conjunctival allergen challenge, this double-masked, randomized by eye, parallel-group study included four ...
| Known for Allergic Conjunctivitis | Olopatadine 02 | Ophthalmic Solution | Onset Action | Signs Symptoms |
BACKGROUND: Epinastine hydrochloride is an antihistamine with mast cell-stabilizing and anti-inflammatory activity.
OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of ophthalmic epinastine in patients with seasonal allergic conjunctivitis (SAC) exposed to environmental allergens.
METHODS: This randomized (age-stratified), double-masked, parallel-group, active- and vehicle-controlled, environmental, Phase III clinical trial was conducted at 6 ophthalmology ...
| Known for Ophthalmic Epinastine | Seasonal Allergic Conjunctivitis | Ocular Itching | Patients Sac | Study Efficacy |
BACKGROUND: The most common form of allergic ocular disease is seasonal allergic conjunctivitis, coinciding with the pollen season and generally associated with rhinitis. Symptoms of allergic conjunctivitis include ocular itching, hyperemia, tearing, mucus production, foreign body sensation, chemosis, and lid edema. Similarly, the primary symptoms of allergic rhinoconjunctivitis are nasal itching, irritation, sneezing, watery rhinorrhea, and congestion combined with ocular itching, ...
| Known for Ophthalmic Solution | Ocular Itching | Seasonal Allergic | Olopatadine Placebo | Nasal Symptoms |
BACKGROUND: Epinastine hydrochloride is a nonsedating antihistamine with a high affinity for histamine H(1) receptors, together with mast cell-stabilizing and anti-inflammatory activities.
OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of topically administered ophthalmic epinastine using the conjunctival antigen challenge (CAC) model in patients with a history of allergic conjunctivitis.
METHODS: This prospective, single-center, randomized, double-masked, ...
| Known for Ophthalmic Epinastine | Allergic Conjunctivitis | Challenge Model | Efficacy Tolerability | Conjunctival Hyperemia |
The Conjunctival Provocation Test Model of Ocular Allergy: Utility for Assessment of an Ocular Corticosteroid, Loteprednol Etabonate
[ PUBLICATION ]
Two studies were conducted using the conjunctival provocation test (CPT) model of ocular allergy. The objective of the first study was to evaluate the sensitivity of the CPT model to a topical corticosteroid. Selected was loteprednol etabonate 0.5%, previously found effective in the treatment of ocular allergy and inflammation. The study was a randomized double-masked, placebo-controlled, paired-comparison of loteprednol etabonate 0.5% (LE), b.i.d. or q.i.d. Sixty subjects who had a ...
| Known for Loteprednol Etabonate | Ocular Allergy | Itching Redness | Conjunctival Provocation | Allergic Diagnostic Techniques |
BACKGROUND: Previous studies have suggested that olopatadine hydrochloride ophthalmic solution 0.2% administered once daily is effective for up to 24 hours after instillation and is well tolerated in adults and children aged > or =3 years.
OBJECTIVE: The goal of this study was to evaluate the efficacy and safety profile of olopatadine 0.2% compared with placebo in patients with seasonal allergic conjunctivitis or rhinoconjunctivitis.
METHODS: This was a 10-week, randomized, ...
| Known for Allergic Conjunctivitis | Ocular Itching | Olopatadine Hydrochloride | Ophthalmic Solution | Redness Treatment |
BACKGROUND: Allergic rhinoconjunctivitis patients are often treated with nasal or systemic allergy therapy, forgoing therapy for ocular symptoms. This treatment regimen leaves important aspects of the allergic reaction untreated and affects quality of life (QoL). The Rhinoconjunctivitis Quality of Life Questionnaire and the Allergic Conjunctivitis Quality of Life Questionnaire quantify separate aspects of QoL.
OBJECTIVE: To determine the benefit gained in QoL, measured by these ...
| Known for Allergic Rhinitis | Olopatadine Hydrochloride | Quality Life | Ocular Symptoms | Seasonal Surveys |
BACKGROUND: Allergic conjunctivitis very often occurs simultaneously with rhinitis in seasonal allergy sufferers. While systemic anti-allergic and antihistaminic agents are effective against many signs and symptoms of allergy, they may not adequately control ocular signs and symptoms in patients with multiple target organ hypersensitivity. Patanol (olopatadine hydrochloride 0.1% ophthalmic solution, Alcon Laboratories, Inc., Fort Worth, TX), a new effective anti-allergic mast cell ...
| Known for Ocular Itching | Allergic Conjunctivitis | Visit 3 | Allergen Challenge | Olopatadine Hydrochloride |
Mark B Abelson: Influence Statistics
| Concept | World rank |
|---|---|
| 02 evaluated | #1 |
| nasapaque | #1 |
| statistical trend day | #1 |
| ophthalmic antihistamine | #1 |
| allergic dibenzoxepins histamine | #1 |
| pnif nis | #1 |
| received levocabastine | #1 |
| exposure ragweed | #1 |
| pollen biocube | #1 |
| study loteprednol etabonate | #1 |
| duration extended blinks | #1 |
| 4 loratadine | #1 |
| iodixanol placebo treatment | #1 |
| symptoms diurnal | #1 |
| contrast allergics | #1 |
| occurrence extended blinks | #1 |
| symptoms allergic conjunctivitis | #1 |
| controlled cac | #1 |
| interblink intervals | #1 |
| ocular allergic reactions | #1 |
| menthol dry | #1 |
| easy disease | #1 |
| 4hour rechallenge | #1 |
| patanol placebo tablet | #1 |
| itchy nose severity | #1 |
| subjects positive reaction | #1 |
| ketorolac antiinflammatory agents | #1 |
| storage tears | #1 |
| itching subject | #1 |
| phenidone ocular inflammation | #1 |
| histamine untreated samples | #1 |
| nasal inflammation score | #1 |
| 16 cac | #1 |
| common ophthalmic preservatives | #1 |
| oncedaily dosing review | #1 |
| chemosis histamine | #1 |
| controlled allergic reaction | #1 |
| ibi ocular protection | #1 |
| conjunctival injection drug | #1 |
| produced whitening | #1 |
| placebo claritin | #1 |
| eye levocabastine | #1 |
| eosinophils conjunctival | #1 |
| levocabastine sodium cromolyn | #1 |
| insite vision | #1 |
| placebo tear | #1 |
Open the FULL List in Excel | |
Key People For Allergic Conjunctivitis
Mark B Abelson:Expert Impact
Concepts for whichMark B Abelsonhas direct influence:Allergic conjunctivitis, Dry eye, Ophthalmic solution, Normal subjects, Allergen challenge, Ocular itching, Ocular allergy, Bepotastine besilate.
Mark B Abelson:KOL impact
Concepts related to the work of other authors for whichfor which Mark B Abelson has influence:Allergic conjunctivitis, Dry eye, Ocular surface, Tear film, Contact lens, Mast cells, Infantile spasms.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |